Glaxo socks more cash into immunotherapy bet

Last year, GlaxoSmithKline ($GSK) traded away most of its cancer assets to Novartis ($NVS) in exchange for the majority of the Swiss drugmaker's vaccines portfolio. But it's not out of the area altogether, and now, it's sweetening a deal with oncology partner Adaptimmune. Glaxo has promised more cash to speed up development of a promising treatment for soft tissue sarcoma, pledging to fund pivotal trials for the immunotherapy. Read more from FierceBiotech

Read more on